Low IL-2 concentration favors generation of early memory T cells over terminal effectors during CAR T-cell expansion

      Adoptive T-cell therapy offers new options for cancer treatment. The therapeutic efficacy of T-cell therapy is linked to the persistence of administrated T cells, which is dependent on T-cell memory. Hence, the need for cells possessing early memory phenotypes in T-cell products is evident. The amount of interleukin-2 (IL-2) supplementation during in vitro expansion affects T-cell proliferation and effector differentiation. Here, we present a simplified and cost-effective expansion method for the production of chimeric antigen receptor (CAR) T cells with potentially improved therapeutic capacity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect